Gulam Hekimoglu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Gulam Hekimoglu has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Kubra Sevgin
Department of Histology and Embryology, Hamidiye International Faculty of Medicine, University of Health Sciences, Istanbul, Turkey
3 shared publications - Muhammetnur Tekayev
University of Health Sciences
3 shared publications - Halime Tuba Canbaz
Department of Histology and Embryology, Hamidiye Faculty of Medicine, University of Health Sciences, 34668 Istanbul, Türkiye
2 shared publications - Tansel Sapmaz
Department of Histology and Embryology, Hamidiye Faculty of Medicine, University of Health Sciences, İstanbul, Türkiye
2 shared publications - Ali Imran Dastan
Department of Medical Directorate Stembio Cord Blood, Cell and Tissue Center Kocaeli Turkey
1 shared publication - Bahar Muezzinoglu
Pathology Department, Istanbul Medipol University, Istanbul, Türkiye
1 shared publication
Latest Publications
- 17 August 2023
- Published by Wiley in Pathology International
- Vol. 73 (10) , 490-496
Lowered IL‐37 gene expression and elevated IL‐37‐producing tissue‐resident immune cells in psoriasis lesional biopsies
Psoriasis is an immune cell‐dependent chronic autoimmune skin disorder. Interleukin 37 (IL‐37) is a cytokine belonging to the IL‐1 family that shows anti‐inflammatory and protective effects in various mouse models of psoriasis. Even though various animal models are used to investigate the pathogenic mechanisms of psoriasis, human clinical studies are still needed to make up for the deficiencies, as animal models generally do not exhibit the complex phenotypic features of human psoriasis. Our study aims to demonstrate the relationship between IL‐37‐producing tissue‐resident immune cells with the pathogenesis of psoriasis. The present study was performed on 28 psoriasis patients and 17 healthy volunteers. The ability of anti‐inflammatory cytokine IL‐37 to impede inflammation and regulate metabolic pathways was assessed by real‐time quantitative polymerase chain reaction. Finally, immunofluorescence double staining for CD4+IL‐37b+, CD68+IL‐37b+, and (forkhead box protein P3) Foxp3+IL‐37b+ was performed. The proportion of CD4+IL‐37b+ T cells, CD68+IL‐37b+ macrophages, and Foxp3+IL‐37b+ T regulatory (Treg) cells was significantly increased in the psoriasis group compared to the control group. IL‐37 gene expression was downregulated in psoriasis when contrasted to the control group. Our findings disclosed that IL‐37‐producing tissue‐resident immune cells might be involved in the pathogenesis of psoriasis, and thus may be a therapeutic target for individuals with psoriasis.
- 17 August 2023
- Published by Wiley in Pathology International
- Vol. 73 (10) , 490-496
Lowered IL‐37 gene expression and elevated IL‐37‐producing tissue‐resident immune cells in psoriasis lesional biopsies
Psoriasis is an immune cell‐dependent chronic autoimmune skin disorder. Interleukin 37 (IL‐37) is a cytokine belonging to the IL‐1 family that shows anti‐inflammatory and protective effects in various mouse models of psoriasis. Even though various animal models are used to investigate the pathogenic mechanisms of psoriasis, human clinical studies are still needed to make up for the deficiencies, as animal models generally do not exhibit the complex phenotypic features of human psoriasis. Our study aims to demonstrate the relationship between IL‐37‐producing tissue‐resident immune cells with the pathogenesis of psoriasis. The present study was performed on 28 psoriasis patients and 17 healthy volunteers. The ability of anti‐inflammatory cytokine IL‐37 to impede inflammation and regulate metabolic pathways was assessed by real‐time quantitative polymerase chain reaction. Finally, immunofluorescence double staining for CD4+IL‐37b+, CD68+IL‐37b+, and (forkhead box protein P3) Foxp3+IL‐37b+ was performed. The proportion of CD4+IL‐37b+ T cells, CD68+IL‐37b+ macrophages, and Foxp3+IL‐37b+ T regulatory (Treg) cells was significantly increased in the psoriasis group compared to the control group. IL‐37 gene expression was downregulated in psoriasis when contrasted to the control group. Our findings disclosed that IL‐37‐producing tissue‐resident immune cells might be involved in the pathogenesis of psoriasis, and thus may be a therapeutic target for individuals with psoriasis.
- Open Access
- 15 May 2023
- Published by LookUs Bilisim A.S. in Medical Records
- Vol. 5 (2) , 269-76
Oxidative Stress Elevates eNOS Expression and VSMCs Proliferation of the Umbilical Vein of GDM Mothers
Aim: Gestational diabetes mellitus (GDM) is associated with an increased risk of fetal and maternal complications, such astype 2 DM (diabetes mellitus) and cardiovascular disease (CVD). This study aimed to predict the potential for future vascular complications in mothers with GDM by evaluating oxidative stress, endothelial NO synthase (eNOS) expression, and vascular smooth muscle cell (VSMC) proliferation in the umbilical vessels of mothers with GDM. Material and Methods: Subjects were divided into two groups: the normoglycemic control (NGC) group (n = 10) and the GDM group (n = 12). Expression of eNOS and production of reactive oxygen species (ROS) in human umbilical vein endothelial cells (HUVECs) were determined. The mitochondrial mass of HUVECs was evaluated by spectrofluorometry. VSMC proliferation was ascertained in vitro with an EdU cell proliferation assay. Advanced glycation end products (AGEs) accumulation was measured by ELISA and assessed by immunohistochemical staining Results: VSMC proliferation, eNOS expression, and ROS production in HUVECs were significantly increased, and greater immunohistochemical staining to AGEs was observed in endothelium in GDM. Conclusion: Increased oxidative stress, which elevates eNOS expression and VSMC proliferation in the umbilical vessels of mothers with GDM, may be a sign that mothers have a high potential for developing diabetes or cardiovascular disease in the future.
- 15 May 2023
- Published by LookUs Bilisim A.S. in Medical Records
- Vol. 5 (2) , 269-76
Open AccessOxidative Stress Elevates eNOS Expression and VSMCs Proliferation of the Umbilical Vein of GDM Mothers
Aim: Gestational diabetes mellitus (GDM) is associated with an increased risk of fetal and maternal complications, such astype 2 DM (diabetes mellitus) and cardiovascular disease (CVD). This study aimed to predict the potential for future vascular complications in mothers with GDM by evaluating oxidative stress, endothelial NO synthase (eNOS) expression, and vascular smooth muscle cell (VSMC) proliferation in the umbilical vessels of mothers with GDM. Material and Methods: Subjects were divided into two groups: the normoglycemic control (NGC) group (n = 10) and the GDM group (n = 12). Expression of eNOS and production of reactive oxygen species (ROS) in human umbilical vein endothelial cells (HUVECs) were determined. The mitochondrial mass of HUVECs was evaluated by spectrofluorometry. VSMC proliferation was ascertained in vitro with an EdU cell proliferation assay. Advanced glycation end products (AGEs) accumulation was measured by ELISA and assessed by immunohistochemical staining Results: VSMC proliferation, eNOS expression, and ROS production in HUVECs were significantly increased, and greater immunohistochemical staining to AGEs was observed in endothelium in GDM. Conclusion: Increased oxidative stress, which elevates eNOS expression and VSMC proliferation in the umbilical vessels of mothers with GDM, may be a sign that mothers have a high potential for developing diabetes or cardiovascular disease in the future.
- Open Access
- 3 March 2023
- Published by The European Research Journal in The European Research Journal
- Vol. 9 (2) , 178-185
Ameliorative effects of apigenin on a rat model of endometriosis
Objectives: Apigenin and parthenolide as natural products have potent antioxidant and anti-inflammatory outcomes that could make them a perfect option for endometriosis therapy. This study aimed to determine the effects of apigenin and parthenolide on created endometrial implants in a rat model of endometriosis. Methods: Thirty-nine mature, female Sprague-Dawley rats were assigned randomly to six experimental groups four weeks after endometriosis induction. Group 1 (n = 5): Control (CTRL) that opened and closed the abdomen; Group 2 (n = 6): Peritoneal and ovarian endometriosis (POE) + drug-free; Group 3 (n = 7): POE+ Apigenin (APG) (50 mg/kg); Group 4 (n = 7): POE+ Parthenolide (PTL) (10 mg/kg); Group 5 (n = 7): POE+ Apigenin (APG) (50 mg/kg) + Parthenolide (PTL) (10 mg/kg); Group 6 (n = 7): POE+ DMSO. An endometriosis model was created, and histopathological analysis and biochemical evaluation were performed. Serum and peritoneal levels of pro-and-anti-inflammatory cytokine, and oxidative stress of implant tissue were measured. Results: Serum IL-37 levels decreased significantly in the APG-treated group compared to the drug-free group (p = 0.016). The peritoneum and ovary endometriosis histopathologic scores were significantly lower in APG-treated (p = 0.001) and PTL-treated (p = 0.001) groups in comparison to the drug-free group. The oxidative stress index (OSI) values were increased statistically significantly in ovary endometriosis tissue in the drug-free group, (p = 0.001). However, compared to the drug-free group, OSI values decreased statistically significantly in the APG-treated group (p = 0.003).Conclusions: The application of apigenin caused a decrease in oxidative stress and an improvement in histopathological grade. Apigenin may be a novel therapeutic agent for the treatment of endometriosis.
- 3 March 2023
- Published by The European Research Journal in The European Research Journal
- Vol. 9 (2) , 178-185
Open AccessAmeliorative effects of apigenin on a rat model of endometriosis
Objectives: Apigenin and parthenolide as natural products have potent antioxidant and anti-inflammatory outcomes that could make them a perfect option for endometriosis therapy. This study aimed to determine the effects of apigenin and parthenolide on created endometrial implants in a rat model of endometriosis. Methods: Thirty-nine mature, female Sprague-Dawley rats were assigned randomly to six experimental groups four weeks after endometriosis induction. Group 1 (n = 5): Control (CTRL) that opened and closed the abdomen; Group 2 (n = 6): Peritoneal and ovarian endometriosis (POE) + drug-free; Group 3 (n = 7): POE+ Apigenin (APG) (50 mg/kg); Group 4 (n = 7): POE+ Parthenolide (PTL) (10 mg/kg); Group 5 (n = 7): POE+ Apigenin (APG) (50 mg/kg) + Parthenolide (PTL) (10 mg/kg); Group 6 (n = 7): POE+ DMSO. An endometriosis model was created, and histopathological analysis and biochemical evaluation were performed. Serum and peritoneal levels of pro-and-anti-inflammatory cytokine, and oxidative stress of implant tissue were measured. Results: Serum IL-37 levels decreased significantly in the APG-treated group compared to the drug-free group (p = 0.016). The peritoneum and ovary endometriosis histopathologic scores were significantly lower in APG-treated (p = 0.001) and PTL-treated (p = 0.001) groups in comparison to the drug-free group. The oxidative stress index (OSI) values were increased statistically significantly in ovary endometriosis tissue in the drug-free group, (p = 0.001). However, compared to the drug-free group, OSI values decreased statistically significantly in the APG-treated group (p = 0.003).Conclusions: The application of apigenin caused a decrease in oxidative stress and an improvement in histopathological grade. Apigenin may be a novel therapeutic agent for the treatment of endometriosis.